4.7 Article

Type-4 Phosphodiesterase (PDE4) Blockade Reduces NETosis in Cystic Fibrosis

期刊

FRONTIERS IN PHARMACOLOGY
卷 12, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2021.702677

关键词

cystic fibrosis; neutrophil; neutrophil extracellular traps; lung damage; PDE4 inhibition

资金

  1. Italian Cystic Fibrosis Research Foundation [21/2011, 16/2013]
  2. Fondazione Negri Sud Onlus
  3. MIUR [D.M. 44/08]
  4. Italian Ministry of Health [L548/93]
  5. Italian Cystic Fibrosis Research Foundation
  6. Italian Cystic Fibrosis Research Foundation (CFaCore)

向作者/读者索取更多资源

This study demonstrates that PDE4 inhibitors can control NETosis in CF-relevant models, showing efficacy in neutrophils from both healthy volunteers and CF patients. In a mouse model of chronic Pseudomonas aeruginosa infection, aerosol treatment with the selective PDE4 inhibitor roflumilast resulted in reduced free DNA in the BALF along with decreased citrullination of histone H3 in neutrophils in the airways.
Neutrophilic inflammation is a key determinant of cystic fibrosis (CF) lung disease. Neutrophil-derived free DNA, released in the form of extracellular traps (NETs), significantly correlates with impaired lung function in patients with CF, underlying their pathogenetic role in CF lung disease. Thus, specific approaches to control NETosis of neutrophils migrated into the lungs may be clinically relevant in CF. We investigated the efficacy of phosphodiesterase (PDE) type-4 inhibitors, in vitro, on NET release by neutrophils from healthy volunteers and individuals with CF, and in vivo, on NET accumulation and lung inflammation in mice infected with Pseudomonas aeruginosa. PDE4 blockade curbed endotoxin-induced NET production and preserved cellular integrity and apoptosis in neutrophils, from healthy subjects and patients with CF, challenged with endotoxin, in vitro. The pharmacological effects of PDE4 inhibitors were significantly more evident on CF neutrophils. In a mouse model of Pseudomonas aeruginosa chronic infection, aerosol treatment with roflumilast, a selective PDE4 inhibitor, gave a significant reduction in free DNA in the BALF. This was accompanied by reduced citrullination of histone H3 in neutrophils migrated into the airways. Roflumilast-treated mice showed a significant improvement in weight recovery. Our study provides the first evidence that PDE4 blockade controls NETosis in vitro and in vivo, in CF-relevant models. Since selective PDE4 inhibitors have been recently approved for the treatment of COPD and psoriasis, our present results encourage clinical trials to test the efficacy of this class of drugs in CF.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据